Related Experiment Video
Updated: Jun 17, 2025
02:47
Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
Published on: May 12, 2023
1.3K
Emerging Therapeutic Strategies in Cardiovascular Diseases
Rajinderpal Singh1, Sohbat Kaur Chandi1, Seerat Sran2
1Internal Medicine, Government Medical College Amritsar, Amritsar, IND.
Cureus
|August 12, 2024
Summary
Innovative cardiovascular therapies, including new drugs, gene therapy, and medical devices, offer hope for better patient outcomes. Addressing challenges like cost and regulation is key to transforming cardiovascular care globally.
Area of Science:
- Cardiology
- Pharmacology
- Biotechnology
- Medical Devices
- Personalized Medicine
Background:
- Cardiovascular diseases (CVDs) are the leading global cause of mortality, with nearly 20 million deaths annually.
- Traditional CVD therapies face limitations due to aging populations and lifestyle factors, necessitating novel approaches.
- A rising prevalence of CVDs worldwide underscores the urgent need for advanced and effective treatment strategies.
Purpose of the Study:
- To review and highlight innovative therapeutic strategies for cardiovascular diseases (CVDs).
- To discuss emerging pharmacological, biological, and technological advancements in cardiovascular care.
- To explore the potential of personalized medicine and identify challenges in adopting new CVD treatments.
Main Methods:
- Review of emerging pharmacological treatments like PCSK9 and SGLT2 inhibitors.
- Analysis of advanced biological therapies including gene, stem cell, and RNA-based treatments.
- Evaluation of innovative medical devices, minimally invasive procedures, and wearable technology.
- Exploration of personalized medicine approaches driven by genetic profiling and biomarkers.
Main Results:
- Emerging pharmacological agents significantly reduce cardiovascular events and mortality.
- Biological therapies show promise in repairing and regenerating cardiovascular tissues.
- Advanced devices and technologies enable early diagnosis, continuous monitoring, and remote patient care.
- Personalized medicine enhances treatment efficacy and minimizes adverse effects.
Conclusions:
- Innovative therapies, including pharmacological, biological, and technological advancements, hold significant potential to transform cardiovascular care.
- Overcoming challenges such as regulatory hurdles, cost, accessibility, and ethical considerations is crucial for widespread adoption.
- Interdisciplinary collaboration and continued research are essential to accelerate the development and implementation of next-generation CVD treatments.
- A future of personalized, effective, and accessible cardiovascular care is achievable through strategic integration of emerging therapies.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
406
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.1K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.1K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
425
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
425
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
474
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
474
01:22Heart Failure Drugs: β-Blockers
326
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
326
01:16Antianginal Drugs: Nitrates and β-Blockers
557
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
557